Skip to main content
Log in

Advanced hybrid closed-loop MiniMed 780G cost effective for T1DM

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. 2019 Swedish krona

Reference

  • Jendle J, et al. The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden Diabetes Therapy : 1 Oct 2021. Available from: URL: https://doi.org/10.1007/s13300-021-01157-0

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Advanced hybrid closed-loop MiniMed 780G cost effective for T1DM. PharmacoEcon Outcomes News 889, 2 (2021). https://doi.org/10.1007/s40274-021-08090-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-08090-8

Navigation